Milos J. Janicek, MD, PhD, MHCM

Clinical Professor, Radiology

Milos Janicek
88 E. Newton St Newton Pavilion


Milos Janicek, MD, PhD, serves as an Associate Professor of Radiology in Body Imaging at the Chobanian and Avedisian School of Medicine. For several years he served as Section Chief in the department of Radiology. As a former fellow at the Dana Farber Cancer Institute, he developed a special interest in tumor Imaging and infrared imaging application in tumor biology and continues to conduct research in these subfields. Dr. Janicek holds duel certification in diagnostic radiology and nuclear medicine by the American Board of Radiology.


I have chosen the field of Radiology with intention to combine clinical contribution with my strong interest in research. Looking back at my very diverse, yet, productive carrier, I believe that I have accomplished a lot nearing my goal: In 1986, I joined BWH, HMS as a research fellow. I explored modeling of new vessel formation after arterial occlusion, investigating the natural history of endothelial injury, and clinical implications of platelet activation. My proudest cooperation was that with J. Folkman’s laboratory exploring the angiogenesis inhibition. At the DFCI, I focused on the imaging of secondary malignant skeletal disease and of aggressive malignant lymphoma. My interest in oncologic imaging, particularly related to prognostication of sequential imaging is the essence of my current BMC research of Immuno-Therapies on model of Malignant Melanoma applying prior experience from PET-CT and gallium-67 in lymphoma. I developed a novel imaging application using infrared imaging for re-staging of cancer patients, using tumor perfusion assessment with PET and Doppler ultrasound as an index of very early therapy response in multi-center trial of Gastrointestinal Stromal Tumor in collaboration with Novartis Pharmaceuticals. I served in CALGB panels of Lymphoma Experts on imaging in Immunotherapy for low grade lymphomas (LEXCOR group) organized by IDEC pharmaceutical, San Diego, CA leading to one of major modern epics: RITUXAN and ZEVALIN therapy of multiple tumors. At BMC, I was involved in organizing my own multidisciplinary team around Neuroendocrine Tumor, monitoring and therapeutic implications of functional imaging, Y-90 therapy, and bridging to Ga-68 DOTATATE. It was a foundation of my current interest in a novel approach to RECIST scoring in era of Immune therapies (IT). Replacing traditional restaging with measure of “therapeutic Impact” of treatments discussed at ASCO 2019 and ASCO-SITC 2020 and ARRS 2023. Focusing on Malignant melanoma and IT with our Oncology Group will test our research on upcoming multicenter biomarker driven Anti-PD-1 therapy in Melanoma.


  • Palacký University, Olomouc, MD
  • Jan Evangelista Purkyne University, PhD


  • Published on 8/1/2014

    Zhu V, de Las Morenas A, Janicek M, Hartshorn K. Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D. J Gastrointest Oncol. 2014 Aug; 5(4):E84-7. PMID: 25083313.

    Read at: PubMed
  • Published on 9/20/2011

    Janicek MJ, Camaya VM. Probably benign findings, BIRADS category 3 (MR-Bi3), on magnetic resonance imaging of the breast (BrMR): Is repeated MRI an alternative to biopsy? J Clin Oncol. 2011 Sep 20; 29(27_suppl):21. PMID: 27958027.

    Read at: PubMed
  • Published on 5/20/2011

    Janicek MJ, Camaya VM, Naddaff D. Value of close follow-up for "probably benign findings," BIRADS category 3 (MR-Bi3), on magnetic resonance imaging of the breast (BrMR). J Clin Oncol. 2011 May 20; 29(15_suppl):e11060. PMID: 28023441.

    Read at: PubMed
  • Published on 4/8/2011

    Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL. Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Pract Radiat Oncol. 2011 Apr-Jun; 1(2):115-25. PMID: 24673925.

    Read at: PubMed
  • Published on 6/20/2010

    Teneriello MG, Gordon AN, Lim P, Janicek M. Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report. J Clin Oncol. 2010 Jun 20; 28(18_suppl):LBA5008. PMID: 27937443.

    Read at: PubMed
  • Published on 6/1/2005

    Mendelson DS, Brewer M, Janicek M, Breitenbach E, Barrett E, Hamilton M, Ptazynski M, van Duym C, Gordon M. Phase I study of OSI-211 (liposomal lurtotecan) in combination with liposomal doxorubicin (LD) every 3 weeks in patients (pts) with advanced solid tumors; final analysis suggests benefit in refractory ovarian cancer (OC). J Clin Oncol. 2005 Jun; 23(16_suppl):2074. PMID: 27946920.

    Read at: PubMed
  • Published on 12/1/2003

    Janicek MJ, Demetri G, Janicek MR, Shaffer K, Fauci MA. Dynamic infrared imaging of newly diagnosed malignant lymphoma compared with Gallium-67 and Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography. Technol Cancer Res Treat. 2003 Dec; 2(6):571-8. PMID: 14640768.

    Read at: PubMed
  • Published on 9/15/2002

    Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002 Sep 15; 20(18):3772-84. PMID: 12228197.

    Read at: PubMed
  • Published on 8/15/2002

    Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80. PMID: 12181401.

    Read at: PubMed
  • Published on 3/1/2002

    Oh WK, Loda M, Kantoff PW, Janicek M. Progressive sclerosis of isolated foot metastasis of prostate cancer. J Urol. 2002 Mar; 167(3):1392. PMID: 11832744.

    Read at: PubMed

View 23 more publications: View full profile at BUMC

View all profiles